Literature DB >> 36214924

Liver metastases 2 years after resection of a very-low-risk duodenal gastrointestinal stromal tumor: a case report.

Junya Mita1, Kazuhiro Tada2, Yusuke Kuboyama3, Shoji Hiroshige2, Shun Nakamura2, Junichi Takahashi2, Kazuhito Sakata2, Hiroshi Mizuuchi2, Taro Oba2, Fumitaka Yoshizumi2, Kentaro Iwaki2, Hideya Takeuchi2, Kiyoshi Kajiyama2, Kengo Fukuzawa2.   

Abstract

BACKGROUND: Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors, but are the most common mesenchymal tumors of the gastrointestinal tract. The risk classification of GISTs is based on the tumor size, mitotic index, tumor site, and presence of tumor rupture. Recurrence in the very-low-risk group is extremely rare. We herein report a case of liver metastases 2 years after resection of a very-low-risk duodenal GIST. CASE
PRESENTATION: A 57-year-old woman presented to the hospital for evaluation of melena. Esophagogastroduodenoscopy showed bleeding from the exposed blood vessels at the top of a submucosal tumor approximately 20 mm in size located in the second (descending) part of the duodenum, and the bleeding was controlled with electrocoagulation. A GIST was suspected, and the patient underwent wedge resection of the duodenum. The resected specimen contained a 16- × 12-mm (< 20-mm) white submucosal tumor composed of spindle cells with a mitotic count of 4 per 50 high-power fields, and a histologically negative margin was achieved. Immunochemical analysis revealed positive tumor staining for c-kit protein and alpha-smooth muscle actin and negative staining for CD34, desmin, and S-100 protein. Therefore, the tumor was diagnosed as a very-low-risk duodenal GIST based on the Fletcher classification and modified Fletcher classification (Joensuu classification). The postoperative course was uneventful, and the patient was discharged on postoperative day 11. At the follow-up visit 2 years postoperatively, contrast-enhanced computed tomography revealed liver tumors in S8 and S6 measuring 26 × 24 and 10 × 10 mm, respectively. Both lesions showed peripheral dominant hyperenhancement with hypoenhancement inside, indicating tissue degeneration within the tumors. These imaging findings closely resembled those of the duodenal GIST. Hence, the patient was diagnosed with liver metastases of GIST 2 years postoperatively. She was subsequently started on treatment with 400 mg of imatinib. At the time of this writing (2 months after diagnosis), the patient was clinically well and asymptomatic and was continuing imatinib therapy.
CONCLUSIONS: Recurrence of very-low-risk GISTs is extremely rare. Even a small GIST with low mitotic activity can never be considered completely benign, and long-term follow-up is necessary.
© 2022. The Author(s).

Entities:  

Keywords:  GIST; Imatinib; Mitotic rate

Year:  2022        PMID: 36214924      PMCID: PMC9550939          DOI: 10.1186/s40792-022-01551-1

Source DB:  PubMed          Journal:  Surg Case Rep        ISSN: 2198-7793


  16 in total

1.  Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  P G Casali; L Jost; P Reichardt; M Schlemmer; J-Y Blay
Journal:  Ann Oncol       Date:  2008-05       Impact factor: 32.976

Review 2.  Gastrointestinal stromal tumors: pathology and prognosis at different sites.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Semin Diagn Pathol       Date:  2006-05       Impact factor: 3.464

Review 3.  Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

Authors:  J-Y Blay; S Bonvalot; P Casali; H Choi; M Debiec-Richter; A P Dei Tos; J-F Emile; A Gronchi; P C W Hogendoorn; H Joensuu; A Le Cesne; J McClure; J Mac Clure; J Maurel; N Nupponen; I Ray-Coquard; P Reichardt; R Sciot; S Stroobants; M van Glabbeke; A van Oosterom; G D Demetri
Journal:  Ann Oncol       Date:  2005-04       Impact factor: 32.976

Review 4.  Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Authors:  M Miettinen; J Lasota
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

5.  Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases.

Authors:  Markku Miettinen; Janusz Kopczynski; Hala R Makhlouf; Maarit Sarlomo-Rikala; Hajnalka Gyorffy; Allen Burke; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2003-05       Impact factor: 6.394

6.  GIST suture-line recurrence at a gastrojejunal anastomosis 8 years after gastrectomy: can GIST ever be described as truly benign? A case report.

Authors:  Alexandros Papalambros; Athanasios Petrou; Nicholas Brennan; Kostantinos Bramis; Evangelos Felekouras; Efstathios Papalambros
Journal:  World J Surg Oncol       Date:  2010-10-14       Impact factor: 2.754

7.  Risk stratification of patients diagnosed with gastrointestinal stromal tumor.

Authors:  Heikki Joensuu
Journal:  Hum Pathol       Date:  2008-10       Impact factor: 3.466

8.  Duodenal GIST: a single center experience.

Authors:  Alexander Beham; Inga-Marie Schaefer; Silke Cameron; Katharina von Hammerstein; Laszlo Füzesi; Giuliano Ramadori; Michael B Ghadimi
Journal:  Int J Colorectal Dis       Date:  2012-02-22       Impact factor: 2.571

9.  Gastrointestinal Bleeding Is an Independent Risk Factor for Poor Prognosis in GIST Patients.

Authors:  Qi Liu; Yuji Li; Ming Dong; Fanmin Kong; Qi Dong
Journal:  Biomed Res Int       Date:  2017-05-15       Impact factor: 3.411

10.  Prognostic value of tumor necrosis in gastrointestinal stromal tumor: A meta-analysis.

Authors:  Mengshi Yi; Lin Xia; Yan Zhou; Xiaoting Wu; Wen Zhuang; Yi Chen; Rui Zhao; Qianyi Wan; Liang Du; Yong Zhou
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.